These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37011599)

  • 21. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
    Murphy SA; Antman EM; Wiviott SD; Weerakkody G; Morocutti G; Huber K; Lopez-Sendon J; McCabe CH; Braunwald E;
    Eur Heart J; 2008 Oct; 29(20):2473-9. PubMed ID: 18682445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.
    Crimi G; Morici N; Ferrario M; Ferri LA; Piatti L; Grosseto D; Cacucci M; Mandurino Mirizzi A; Toso A; Piscione F; De Carlo M; Elia LR; Trimarco B; Bolognese L; Bovenzi FM; De Luca G; Savonitto S; De Servi S
    J Am Heart Assoc; 2019 Jan; 8(2):e010956. PubMed ID: 30636561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
    Abusnina W; Al-Abdouh A; Bizanti A; Gill G; Houssien A; Alshebani Y; Kanmanthareddy A; Dahal K
    Cardiovasc Revasc Med; 2022 May; 38():54-60. PubMed ID: 34384690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of adverse events associated with P2Y12 receptor inhibitors stratified by academic research consortium for high bleeding risk criteria in acute coronary syndrome.
    Fujii T; Endo S; Tsuchiya R; Nagamatsu H; Kasai S; Kawamura Y; Yoshimachi F; Ikari Y
    Int J Cardiol; 2023 Mar; 375():1-6. PubMed ID: 36649890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization.
    Park KH; Jeong MH; Kim HK; Ahn TH; Seung KB; Oh DJ; Choi DJ; Kim HS; Gwon HC; Seong IW; Hwang KK; Chae SC; Kim KB; Kim YJ; Cha KS; Oh SK; Chae JK;
    J Cardiol; 2018 Jan; 71(1):36-43. PubMed ID: 28673508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
    Lahu S; Ndrepepa G; Neumann FJ; Menichelli M; Bernlochner I; Richardt G; Wöhrle J; Witzenbichler B; Hemetsberger R; Mayer K; Akin I; Cassese S; Gewalt S; Xhepa E; Kufner S; Valina C; Sager HB; Joner M; Ibrahim T; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):687-694. PubMed ID: 35191982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel.
    Ng AK; Ng PY; Ip A; Lau KK; Siu CW
    Stroke Vasc Neurol; 2022 Aug; 7(4):310-318. PubMed ID: 35264399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial.
    Yan AT; Roe MT; Neely M; Cyr DD; White H; Fox KAA; Prabhakaran D; Armstrong PW; Ohman EM; Goodman SG
    Coron Artery Dis; 2018 Sep; 29(6):469-476. PubMed ID: 29652672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
    Scirica BM; Bergmark BA; Morrow DA; Antman EM; Bonaca MP; Murphy SA; Sabatine MS; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2020 Mar; 75(10):1095-1106. PubMed ID: 32164882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
    Wiviott SD; Desai N; Murphy SA; Musumeci G; Ragosta M; Antman EM; Braunwald E
    Am J Cardiol; 2011 Oct; 108(7):905-11. PubMed ID: 21816379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
    J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
    Sawayama Y; Yamamoto T; Tomita Y; Asada K; Yagi N; Fukuyama M; Miyamoto A; Sakai H; Ozawa T; Isono T; Hira D; Terada T; Horie M; Nakagawa Y
    Circ J; 2020 Aug; 84(9):1575-1581. PubMed ID: 32713878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
    Chin CT; Boden WE; Roe MT; Neely B; Neely ML; Leiva-Pons JL; Corbalán R; Gottlieb S; Dalby AJ; Armstrong PW; Prabhakaran D; Fox KA; White HD; Ohman EM; Winters KJ; Schiele F
    Heart; 2016 Aug; 102(15):1221-9. PubMed ID: 27030601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
    Curr Med Res Opin; 2014 Nov; 30(11):2207-16. PubMed ID: 25034466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
    Wilcox R; Iqbal K; Costigan T; Lopez-Sendon J; Ramos Y; Widimsky P
    Curr Med Res Opin; 2014 Nov; 30(11):2193-205. PubMed ID: 25025610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
    Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
    Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
    Wiviott SD; White HD; Ohman EM; Fox KA; Armstrong PW; Prabhakaran D; Hafley G; Lokhnygina Y; Boden WE; Hamm C; Clemmensen P; Nicolau JC; Menozzi A; Ruzyllo W; Widimsky P; Oto A; Leiva-Pons J; Pavlides G; Winters KJ; Roe MT; Bhatt DL
    Lancet; 2013 Aug; 382(9892):605-13. PubMed ID: 23953385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.